News

Sales of Cancer Immunotherapy to Grow 1.7X by 2025

A recent report published by Fact.MR points towards disequilibrium in the distribution of cancer immunotherapy in developing and developed regions. In the U.S., high frequency of knowledge-based awareness campaigns encourages individuals to undergo cancer diagnostics, and government-led insurance plans cover high treatment spending.

In stark contrast, developing countries such as Brazil and Argentina lack primary cancer treatment tools. A similar scenario is witnessed in South Africa, where the mortality rate is high, owing to the late diagnosis of cancer. Developing countries of Asia Pacific with high population density and average penetration of quality treatment are serving as high potential cancer immunotherapy markets.

For detailed insights on enhancing your product footprint, request for a sample here- https://www.factmr.com/connectus/sample?flag=S&rep_id=4367&utm_source=totalash&utm_medium=Prasad

Analysing a number of dynamics, the Fact.MR study foresees high opportunities in developing regions such as Latin America, the Middle East & Africa, and Asia Pacific, and projects nearly 1.7X growth of the cancer immunotherapy market during the forecast period (2020-2025).

market share analysis in key regions in cancer immunotherapy market

Key Highlights of Cancer Immunotherapy Market Study

  • Qualitative approach of therapeutic development turns highly cost-intensive for players in the cancer immunotherapy market. Additionally, high product rejection in trial phases leads to huge losses, which discourages manufacturers towards the development of new therapeutics.
  • Progressive rise in the popularity of generic drugs, on account of the affordability factor, is diverting the patient base from spending on branded drugs, thereby weakening the sales prospects of manufacturers.

For critical insights on this market, request for methodology here- https://www.factmr.com/connectus/sample?flag=RM&rep_id=4367&utm_source=totalash&utm_medium=Prasad

  • Incentives offered by central healthcare authorities on development of ‘orphan drugs’ are encouraging established manufacturers to venture into this space.
  • Though hospitals are holding a dominant position as end users in the cancer immunotherapy market, a shift of patients towards clinics will remain noteworthy for market players, on account of shorter wait windows and improvements in healthcare services offered by these institutions.

Cancer Immunotherapy Market – Assessment of Key Segments

The study encompasses market attractiveness analysis, by therapy, cancer type, end user, and region. Market size and forecasts for each segment have been provided in the context of global and regional markets. The cancer immunotherapy market has been analysed based on expected demand. All key end users have been considered, and potential applications have been estimated on the basis of secondary sources and feedback from primary respondents. Regional demand patterns have been considered while estimating the market for various end users of cancer immunotherapy in different regions.

Therapy
  • Monoclonal Antibodies
  • Immune Checkpoint Inhibitors
    • PD-1/PD-L1
    • CTLA-4
  • Immune System Modulators
  • Cancer Vaccines
  • Others
Cancer Type
  • Lung Cancer
  • Colorectal Cancer
  • Breast Cancer
  • Prostate Cancer
  • Melanoma
  • Blood Cancer
  • Others
End User
  • Hospitals
  • Ambulatory Surgical Centres
  • Cancer Research Centres
  • Clinics
Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

For in-depth competitive analysis, buy now – https://www.factmr.com/checkout/4367?utm_source=totalash&utm_medium=Prasad

Pfizer, Inc. best illustrates this strategy. The company has taken multiple initiatives such as collaborations, alliances, mergers, and licensing agreements to launch biologics and receive orphan status for its products. Monetary support from governments to manufacturers, with an intent to develop a promising pipeline of cancer therapeutics, is attracting a large number of new entrants, especially in North America. However, leading players would encounter a low threat of new entrants, on account of their high developmental knowhow and strong distribution networks.

Read More Trending and Similar Reports from Fact.MR – http://www.globenewswire.com/en/news-release/2018/12/21/1677591/0/en/Fiducial-Marker-Effectiveness-in-Prostate-Cancer-Diagnosis-Drives-Adoption-Excellent-Target-Precision-Remains-the-Key-USP.html

About Us:

Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Our sales offices in United States and Dublin, Ireland. Headquarter based in Dubai, UAE. Reach out to us with your goals, and we’ll be an able research partner.

Contact:

US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583

Corporate Headquarter:
Unit No: AU-01-H Gold Tower (AU),
Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers,
Dubai, United Arab Emirates
Email: sales@factmr.com
Visit Our Website: https://www.factmr.com

Tags

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button